Neuroone Med Technologies Corp Stock Price, News & Analysis

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) will host a conference call on February 14, 2023, at 4:30 PM ET, to discuss its financial results for the fiscal first quarter 2023, ending December 31, 2022. The call will also include a corporate update. Interested parties can join the call via dial-in at 877-405-1216 or through a live webcast here. NeuroOne specializes in minimally invasive solutions for neurological disorders, aiming to enhance surgical care and reduce costs.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) reported its fiscal year 2022 achievements and outlined key catalysts for 2023 in a Winter Letter to Shareholders. CEO Dave Rosa highlighted the launch of their Evo® sEEG diagnostic line in partnership with Zimmer Biomet, as well as an FDA 510(k) submission for a combination diagnostic and ablation electrode system. The company aims to enhance patient outcomes in neurological treatments. NeuroOne's focus remains on disruptive technology developed in collaboration with medical experts, anticipating a productive year ahead for stakeholders.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) reported its fiscal fourth quarter and full year 2022 results, showing product revenue of $69,000 for Q4 and $171,000 for the full year, with a slight decline from the previous year. Collaboration revenue saw a significant increase to $1,942,000 in Q4 and $1,949,000 for the year, driven by the Zimmer Development Agreement. Despite higher operating expenses totaling $3.3 million in Q4, the net loss narrowed to $1.4 million compared to $2.6 million in the previous year. The company ended the year with $11.1 million in cash and no debt.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) hosted a corporate update for its fiscal fourth quarter ended September 30, 2022. The company highlighted significant milestones, including a $3.5 million payment from Zimmer Biomet and FDA 510(k) clearance for its Evo® sEEG Electrode technology, targeting a $100 million market. The initial stocking order has been shipped, and advancements in their OneRF™ ablation system were also reported. NeuroOne's financial standing remains strong with $11.1 million in cash and no debt, preparing for commercial launches in 2023.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) will host a conference call on December 13, 2022, at 4:30 PM Eastern Time, to discuss its fiscal fourth quarter and full fiscal year financial results ending September 30, 2022. The call will also include a corporate update. Participants can join via a live webcast or dial in at 877-407-8293. For further information about the company, known for its innovative solutions in treating neurological disorders, visit n1mtc.com.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced the successful completion of an animal feasibility study for its OneRF™ ablation system, which uses existing sEEG diagnostic electrodes for brain lesioning. The study, guided by Dr. Jamie Van Gompel at the Mayo Clinic, confirmed successful RF ablations that may improve procedure safety. The company plans to submit a 510(k) application for FDA clearance in Q2 2023. Additionally, NeuroOne is advancing therapeutic electrode technologies targeting markets worth $500 million to $6 billion.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced the shipment of its first commercial order of Evo sEEG Electrode technology to Zimmer Biomet, its exclusive global distribution partner. This marks a significant milestone for the company, as the Evo sEEG System is its second FDA 510(k) cleared product, targeting a $100 million market for brain mapping procedures. NeuroOne is also developing additional therapeutic electrode technologies for chronic conditions, with potential market values between $500 million and $6 billion.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced it will ring the Nasdaq closing bell on November 22, 2022, to celebrate its recent FDA 510(k) clearance for the Evo sEEG Electrode technology. This milestone supports commercialization efforts and enhances the functionality of the Evo sEEG System, designed for temporary brain signal monitoring and stimulation. CEO Dave Rosa expressed excitement over this achievement at the iconic ceremony, broadcast live from Times Square, New York City, at 4:00 p.m. ET.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has received FDA 510(k) clearance for its Evo sEEG Electrode technology. This allows for temporary use (less than 30 days) in recording and stimulating electrical signals in the brain. The Evo system is significantly less invasive than traditional cortical electrodes, addressing a $100 million market for diagnostic brain mapping. NeuroOne plans to advance commercialization in partnership with Zimmer Biomet, and is also developing therapeutic electrode technologies targeting markets valued up to $6 billion.